Streetbeat News

OWLT

Owlet, Inc.

Industry

Medical - Devices

Owlet, Inc. operates as a digital parenting platform in the United States. The company's platform focuses on giving real-time data and insights to parents. Its products include Smart Sock, a baby monitor to track an infant's oxygen levels, heart rates, and sleep trends; Dream Sock, an app to assist children for better sleep; Cam, a video streaming app to hear and see baby from anywhere; and Dream Lab, an interactive online platform that assists families in building healthy sleep habits. The company also offers Dream Duo, a monitoring system for baby's sleeping habits and includes wearable sock monitor, HD video, and digital sleep coach. Owlet, Inc. was founded in 2012 and is based in Lehi, Utah.

Open

5.26

Mkt cap

78M

Volume

7.6K

High

5.29

P/E Ratio

-2.73

52-wk high

7.50

Low

5.09

Div yield

N/A

52-wk low

3.20

Owlet shares are trading lower following the announcement of worse-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:05 pm

Owlet shares are trading lower following the announcement of worse-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 10:07 pm

Owlet (NYSE:OWLT) reported Q4 earnings with an EPS of $-0.12, missing estimates by -200% compared to the expected $-0.04. Revenue increased by $9M from the same period last year. Previously, a miss on EPS led to an 8% drop in share price the next day. The company's past earnings performance shows a pattern of not meeting EPS estimates.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:15 pm

Owlet (NYSE:OWLT) reported Q4 2023 adjusted EPS of $(0.120), missing the $(0.040) estimate, with sales of $21.000M also missing the $21.160M estimate. This represents a 75% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 07, 2024 | 9:11 pm

Numerous companies are scheduled to report their quarterly earnings on March 7, 2024, with a mix of projected earnings and losses across various sectors. Notable mentions include CI&T, Stevanato Gr, ABM Industries, Bilibili, BJ's Wholesale Club, Burlington Stores, and many others, indicating a significant day for investors to monitor potential market movements.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 9:49 am

Owlet (NYSE:OWLT) is scheduled to release its quarterly earnings report on March 7, 2024, with an expected EPS of $-0.04. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to varying degrees of share price drops. Owlet's stock performance over the last year has been negative, with a 12.54% decrease. Investors are looking for a beat on the EPS estimate and positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 06, 2024 | 5:02 pm

Owlet has announced a $9M private placement involving the issuance of Series B preferred stock convertible into approximately 1.2 million shares of common stock. Purchasers will also receive warrants to buy 150% more shares at $7.7125 each, exercisable for five years.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:38 pm

Owlet, Inc. reported preliminary Q4 2023 revenue of $21 million, slightly below the estimated $21.160 million.

Portfolio Pulse from Benzinga Newsdesk

February 22, 2024 | 1:42 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Sonoma Pharmaceuticals (SNOA) led the gainers with a 36.0% increase, while Evaxion Biotech (EVAX) saw the largest decline among the losers, dropping 33.1%. Other notable movers included 2seventy bio (TSVT), Vaxart (VXRT), and Trinity Biotech (TRIB) with substantial gains, and SINTX Techs (SINT), Owlet (OWLT), and NexImmune (NEXI) with notable losses.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 5:31 pm

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Theseus Pharmaceuticals (THRX) saw a 34.1% increase, while PaxMedica (PXMD) rose by 19.87%. 180 Life Sciences (ATNF) went up by 17.94% following their Q3 earnings release 3 days prior. Exagen (XGN) and Renalytix (RNLX) also saw gains after their recent earnings reports. Spero Therapeutics (SPRO) increased by 8.1% post Q3 earnings. Conversely, Harrow (HROW) dropped by 22.1%, Tenax Therapeutics (TENX) by 15.89%, Beyond Air (XAIR) by 13.8%, Owlet (OWLT) by 12.55%, TRACON Pharma (TCON) by 10.15%, and Inspire Veterinary (IVP) by 9.8% after their earnings reports.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 9:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.